| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to off-white | [Sequence]
H-Pro-Gly-Gln-Glu-His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH(Disulfide bridge:Cys23-Cys7) |
| Hazard Information | Back Directory | [Uses]
Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research[1][2][3]. | [in vivo]
Vosoritide (subcutaneous injection; 800 μg/kg; once daily; 20 d) treatment leads to improvement in skeletal parameters in Fgfr3 gain-of-function mutation mouse[3]. | Animal Model: | Fgfr3Y367C/+ mice[3] | | Dosage: | 800 μg/kg | | Administration: | Subcutaneous injection; 800 μg/kg; once daily; 20 days | | Result: | Observed phenotypic changes including flattening of the skull, elongation of the snout, improvement of the anterior crossbite, larger paws and digits, and longer and straightened tibias and femurs. |
| [References]
[1] Duggan S. Vosoritide: First Approval. Drugs. 2021 Nov;81(17):2057-2062. DOI:10.1007/s40265-021-01623-w
[2] Shuhaibar LC, et al. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth. JCI Insight. 2021 May 10;6(9):e141426. DOI:10.1172/jci.insight.141426
[3] Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012 Dec 7;91(6):1108-14. DOI:10.1016/j.ajhg.2012.10.014 |
|
|